Potential therapeutic targets in polyglutamine-mediated diseases

Masahisa Katsuno, Hirohisa Watanabe, Masahiko Yamamoto, Gen Sobue

研究成果: Review article

9 引用 (Scopus)

抜粋

Polyglutamine diseases are a group of inherited neurodegenerative disorders that are caused by an abnormal expansion of a trinucleotide CAG repeat, which encodes a polyglutamine tract in the protein-coding region of the respective disease genes. To date, nine polyglutamine diseases are known, including Huntington's disease, spinal and bulbar muscular atrophy, dentatorubral-pallidoluysian atrophy and six forms of spinocerebellar ataxia. These diseases share a salient molecular pathophysiology including the aggregation of the mutant protein followed by the disruption of cellular functions such as transcriptional regulation and axonal transport. The intraneuronal accumulation of mutant protein and resulting cellular dysfunction are the essential targets for the development of disease-modifying therapies, some of which have shown beneficial effects in animal models. In this review, the current status of and perspectives on therapy development for polyglutamine diseases will be discussed.

元の言語English
ページ(範囲)1215-1228
ページ数14
ジャーナルExpert Review of Neurotherapeutics
14
発行部数10
DOI
出版物ステータスPublished - 01-10-2014
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

フィンガープリント Potential therapeutic targets in polyglutamine-mediated diseases' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用